Intercept scores cirrhosis win after NASH safety issue
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals said obeticholic acid (OCA) met the primary endpoint with high statistical significance in the first Phase III clinical trial for the company's lead drug candidate, but just two days earlier Intercept disclosed serious cardiovascular adverse events in a Phase II investigator-sponsored trial.